Human Brain Organoid Technology Platform
1. Customer Use and Applications
Q: How are customers using human brain organoids?
A: NeuraCell’s cortical, midbrain, and striatal organoids are used by biopharma, government, and academic partners for translational research and drug discovery. Biopharma customers apply our organoids in proprietary disease modeling and compound screening programs. Regulatory agencies such as the FDA utilize organoids to evaluate compound safety, drug side effects, and QC reproducibility. Academic and nonprofit researchers use our systems to compare generation protocols or to study isogenic (mutant/CRISPR-corrected) pairs for mechanistic insight into neurological diseases. In select collaborations, NeuraCell also performs custom studies—generating organoids, executing targeted molecular screens, and providing data, lysates, or RNA for customer analysis.
Q: What products are most frequently ordered?
A: Our most requested products are cortical, midbrain, and striatal organoids. Customers value our consistent quality and reproducibility across lines and batches.
Q: Are there services currently requested that are not yet offered?
A: The main variable is production timing rather than capability. Organoid maturation naturally spans 2–6 months, and some customer requests fall outside our current inventory schedule. To address this, we are scaling production frequency to maintain mature organoids in stock—reducing lead times and enabling near-immediate delivery as demand grows.
2. Lead-to-Delivery Process
Q: How do customers typically discover NeuraCell and engage with your team?
A: Most engagement arises from direct scientific interactions—conference presentations, peer-reviewed publications, and referrals—driving qualified traffic to our website and technical discussions with our team.
Q: How is customer information managed and tracked?
A: All project inquiries and orders are logged internally for visibility and follow-up. A CRM system implementation is planned to enhance pipeline management as we scale.
Q: What quality control measures are performed?
A: Identity and purity are verified via immunohistochemistry and qPCR at day 20, and at 2, 4, and 6 months. Viability and morphology metrics are predictive of manufacturing success. Reproducibility is supported by extensive single-cell sequencing data and powered by NeuraCell’s proprietary controlled-release growth factor technology, ensuring high batch-to-batch consistency.
Q: Has functional and morphological characterization been conducted?
A: Yes. We routinely perform size, composition, and cell viability assessments at multiple timepoints to ensure consistent performance and biological relevance.
Q: Do customers receive technical consultation or feasibility support?
A: Absolutely. Each collaboration begins with a technical consultation to align research goals, organoid type, and experimental design. Our scientific team provides ongoing support to optimize study outcomes.
Q: What is the typical delivery timeline?
A: Lead times depend on organoid age requested and alignment with in-house production cycles. As production expands, many requests are fulfilled from existing mature inventory, significantly reducing turnaround time.
Q: What are the standard deliverables and pricing?
A: Unit: Individual organoids (typically 15–30 per order). Price Range: $100–$200 per organoid, depending on age, type, and genetic background. Delivery Format: Live organoids shipped in temperature-controlled containers.
Q: How are customers kept informed about order status?
A: Regular progress updates and shipment confirmations are shared via email to ensure full transparency throughout the project.
Q: How are organoids shipped and stored?
A: Live organoids are shipped in validated, temperature-controlled packaging via FedEx overnight delivery. A cryopreservation workflow is in validation, enabling global distribution and long-term storage flexibility.
Q: What proportion of customers use NeuraCell’s services versus independent studies?
A: Biopharma clients typically conduct internal studies using NeuraCell organoids, while select strategic collaborations involve NeuraCell-led candidate screening and data generation services.
Summary
NeuraCell’s human organoid system combines scientific rigor, manufacturing consistency, and translational relevance. Our platform enables partners to bridge human biology with in vivo modeling, supporting high-confidence drug discovery and validation pipelines.